Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.

Described are methods for preparing radionuclides, such as radionuclides having a high specific activity. The disclosed methods include irradiating target nuclide materials, in solution, with a neutron source. The radionuclides can be separated from the target nuclide material by providing a solid carbon nanostructured material, as a suspension of solids, proximal to the target nuclide material in solution and using the recoil to drive adsorption of the radionuclide onto the solid carbon nanostructured material to transfer the radionuclides from the liquid phase (in solution) to the solid phase (adsorbed to the suspended solid carbon nanostructured material). One or more surfactants can be incorporated into the solution to facilitate formation of a stable suspension of the solid carbon nanostructured material.

Described are methods for preparing radionuclides, such as radionuclides having a high specific activity. The disclosed methods include irradiating target nuclide materials, in solution, with a neutron source. The radionuclides can be separated from the target nuclide material by providing a solid carbon nanostructured material, as a suspension of solids, proximal to the target nuclide material in solution and using the recoil to drive adsorption of the radionuclide onto the solid carbon nanostructured material to transfer the radionuclides from the liquid phase (in solution) to the solid phase (adsorbed to the suspended solid carbon nanostructured material). One or more surfactants can be incorporated into the solution to facilitate formation of a stable suspension of the solid carbon nanostructured material.

Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes various embodiments of the present invention.

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.

Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes various embodiments of the present invention.

Various embodiments of the present invention are directed to polyrotaxanes comprising a poloxamer core and at least one cyclodextrin and methods for treating Niemann-Pick type C (NPC) and imaging (e.g., MRI) using the polyrotaxanes various embodiments of the present invention.

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.

Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.

A .sup.99mTc labeled CB7-GA complex, its synthesis, and its use as an anti-viral and anti-liver disease agent.